India Globalization Capital, Inc. logo

India Globalization Capital, Inc.

IGC
Last price US$0.266
Market cap US$25.6m
12M price change -27.86%
Loading the 12-month Mave Thesis and 1-month news signal

Dashboard Funda..tals Prediction Screener Map

India Globalization Capital, Inc. Overview

Industry: Biotechnology

Sector: Healthcare

India Globalization Capital, Inc. purchases and resells physical infrastructure commodities. It operates through two segments, Infrastructure and Life Sciences. The company rents heavy construction equipment, including motor grader and rollers; and undertakes highway construction contracts. It also develops cannabinoid-based products and therapies, such as hemp-based tinctures to treat anxiety, and enhance the lifestyle of patients suffering from Alzheimer's under the Hyalolex brand name; CBD based tinctures, capsules, and topical analgesic creams to treat pain under the Holief brand name; CBD powered beauty and skincare products under the Herbo brand name; and CBD infused beverages under the Sunday Seltzer brand. The company also engages in the wholesale of hemp extract under the Holi Hemp brand; production of products, such as lotions, creams, and oils, as well as white labeling support services; and extraction and distillation of crude oil into hemp extracts. It operates in the United States, India, Colombia, and Hong Kong. The company was incorporated in 2005 and is headquartered in Potomac, Maryland. India Globalization Capital, Inc. purchases and resells physical infrastructure commodities. It operates through two segments, Infrastructure and Life Sciences. The company rents heavy construction equipment, including motor grader and rollers; and undertakes highway construction contracts. It also Read More

Mavefund brings filings, fundamentals, valuation, price history and news for India Globalization Capital, Inc. into one research view. The sections below show what strengthens or weakens the research case.

Score

Reported Results

What the company reported, with filing details kept small.

Filed May 15, 2026

Quarterly result summary

Latest company-filed earnings material is available for source review.

What changed

  • Review the SEC source filing for the full reported results and management commentary.

Guidance / outlook

No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.

SEC filing Open filing

Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

Other recent earnings materials

Prediction-grade evidence

Recent News

Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

No qualified company news in the last 14 days

No recent article passed both the company-relevance and source-reliability checks. Research continues to use the other available filings, fundamentals, market data, and valuation inputs.

Earnings Per Share

Score 1.00/5
India Globalization Capital, Inc. earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

Return on Equity

Score 0.42/5
India Globalization Capital, Inc. exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
India Global... IGC US$25.6m
Zoetis Inc ZTS US$31.9b
IQVIA Holdin... IQV US$34.8b
Agilent Tech... A US$37.9b

Net Margin

Score 0.71/5
India Globalization Capital, Inc. olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
India Global... IGC US$25.6m
Zoetis Inc ZTS US$31.9b
IQVIA Holdin... IQV US$34.8b
Agilent Tech... A US$37.9b

Share Buyback

In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

Leverage

Score 3.89/5
India Globalization Capital, Inc. attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
India Global... IGC US$25.6m
Zoetis Inc ZTS US$31.9b
IQVIA Holdin... IQV US$34.8b
Agilent Tech... A US$37.9b

Financial Statements

Company-reported SEC EDGAR facts organized into the three core statements.

Verified SEC statements load when this section enters view.

Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

Financial Ratio

Yearly Quarterly

Financial
Profitability
Growth
Cash Flow
Financial Health
Efficiency Ratios

India Globalization Capital, Inc. logo

India Globalization Capital, Inc.

US$0.266

US$25.6m

2.31%

-27.86%